NeuroPace Inc (NPCE) stock
NPCENasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/3013% above fair value
$7.56−4.46 (-37.10%)
Close on Nov 13, 2026Market cap $259.49MP/E –Yield 0.00%
NeuroPace price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
NeuroPace's price to sales ratio was 4.3× on Nov 11, 2026, against 6.0× a year earlier. Over the last 5 years it ranged from 0.8× to 6.9×, with a median of 4.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 4.3× | −1.3 |
| 2025 | Dec 31, 2025 | 5.7× | +1.3 |
| 2024 | Dec 31, 2024 | 4.4× | −0.1 |
| 2023 | Dec 29, 2023 | 4.5× | +3.6 |
| 2022 | Dec 30, 2022 | 0.8× | −4.6 |
| 2021 | Dec 31, 2021 | 5.5× | – |
See a number that looks wrong?